anti-CDH17/anti-CD3 bispecific antibody ARB202

{
  "id": "MLC-T-ONC-010452",
  "term": "anti-CDH17/anti-CD3 bispecific antibody ARB202",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody directed against both the T-cell surface antigen CD3 and the tumor-associated antigen (TAA) cadherin-17 (CDH17), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CDH17/anti-CD3 bispecific antibody ARB202 binds to both CD3 on cytotoxic T lymphocytes (CTLs) and CDH17 on CDH17-expressing tumor cells, thereby crosslinking tumor cells and CTLs. This activates and redirects CTLs to CDH17-expressing tumor cells, which results in the CTL-mediated cell death of CDH17-expressing tumor cells. CDH17, a cell surface adhesion protein, is overexpressed in a variety of cancer cell types.",
  "synonyms": [
    "anti-CDH17/CD3 bispecific T-cell engager ARB202",
    "CDH17 x CD3 bispecific antibody ARB202"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-cdh17-anti-cd3-bispecific-antibody-arb202/"
}